CDMO Hovione has announced that Jean-Luc Herbeaux will succeed Guy Villax as CEO of Hovione as of April 1, 2022. Herbeaux joined Hovione as Chief Operating Officer in 2020 after having served in various executive roles at Evonik. Villax will remain a member of the company's board of directors. According to the announcement, the company, which offers inhalation … [Read more...] about Jean-Luc Herbeaux to succeed Guy Villax as Hovione CEO
News
TFF says in vitro studies demonstrate that its inhaled niclosamide may inhibit replication of the Omicron variant of SARS-CoV-2 better than currently available therapies
TFF Pharmaceuticals said that in vitro studies have demonstrated that the company's inhaled niclosamide candidate completely inhibits the Omicron variant of SARS-CoV-2 at a concentration of 1 μM, noting that both nirmatrelvir (Paxlovid) and molnupiravir have been shown to require concentrations of 2.5 μM or greater to completely inhibit Omicron. Enrollment in a … [Read more...] about TFF says in vitro studies demonstrate that its inhaled niclosamide may inhibit replication of the Omicron variant of SARS-CoV-2 better than currently available therapies
AstraZeneca partners with Honeywell on development of HFO-1234ze MDIs
AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans to convert to HFO-1234ze and that a Phase 1 trial of an HFO 1234ze formulation of budesonide/ glycopyrronium/ … [Read more...] about AstraZeneca partners with Honeywell on development of HFO-1234ze MDIs
Armata Pharmaceuticals announces plans for Phase 2 trial of AP-PA02 in NCFB
According to Armata Pharmaceuticals, the FDA has cleared the company's IND for a clinical trial of AP-PA02, an inhaled phage cocktail, in non-cystic fibrosis bronchiectasis (NCFB), and the company plans to initiate a Phase 2 trial of AP-PA02 in NCFB patients this year. AP-PA02 is already in clinical development for the treatment of lung infections in cystic … [Read more...] about Armata Pharmaceuticals announces plans for Phase 2 trial of AP-PA02 in NCFB
Glenmark acquires rights to market Pulmicort Respules in Columbia
Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Columbia has acquired exclusive rights to commercialize AstraZeneca's Pulmicort Respules budesonide inhalation suspension for the treatment of asthma in Columbia. AstraZeneca will manufacture the inhalation suspension and supply the product to Glenmark. Glenmark Executive VP and Global Head, … [Read more...] about Glenmark acquires rights to market Pulmicort Respules in Columbia
Virpax reports positive preclinical toxicology data for Envelta intranasal enkephalin
Virpax Pharmaceuticals said that preclinical studies of the company's Envelta (NES100) enkephalin nasal spray have not identified any toxicology issues in either rats or dogs. The company said that the results support further development of Envelta nasal spray for the treatment of pain, including cancer pain. In February 2021, Virpax announced that pre-clinical … [Read more...] about Virpax reports positive preclinical toxicology data for Envelta intranasal enkephalin
Aptar Pharma breaks ground on new manufacturing facility in Mumbai
OINDP device manufacturer Aptar Pharma recently broke ground on new manufacturing facility on a 3.5 acre site in Mumbai, India, with the groundbreaking taking place on the tenth anniversary of the existing Aptar facility in Mumbai, the company said. Construction on the new facility is expected to be complete by the first quarter of 2023. The existing facility, … [Read more...] about Aptar Pharma breaks ground on new manufacturing facility in Mumbai
Glenmark launches FabiSpray NO nasal spray in India
Glenmark Pharmaceuticals and SaNOtize have announced the approval of FabiSpray nitric oxide nasal spray (NONS) for the treatment of COVID-19 by the Drugs Controller General of India (DCGI) and the launch of the nasal spray in that country. Glenmark announced in August 2021 that it had acquired the rights to the NO nasal spray for the treatment of COVID-19 in India and … [Read more...] about Glenmark launches FabiSpray NO nasal spray in India
FDA approves Lupin’s arformoterol tartrate inhalation solution
The FDA has now fully approved Lupin's ANDA for its generic version of Sunovion's Brovana arformoterol tartrate inhalation solution for the treatment of COPD. Brovana was approved by the FDA in 2006. The agency tentatively approved Lupin's ANDA for the arformoterol tartrate inhalation solution in April 2020, and in June 2021, Lupin announced the launch of an … [Read more...] about FDA approves Lupin’s arformoterol tartrate inhalation solution
Celltrion submits IND for Phase 3 study of inhaled antibody cocktail for COVID-19
Celltrion Group announced that it has submitted an IND application for a Phase 3 trial of an inhaled COVID-19 antibody cocktail for the treatment of mild-to-moderate COVID-19. In July 2021, Celltrion announced that it had partnered with Inhalon Biopharma on development of an inhaled formulation of regdanvimab for the treatment of COVID-19. The proposed Phase 3 trial, … [Read more...] about Celltrion submits IND for Phase 3 study of inhaled antibody cocktail for COVID-19